JP2006514012A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514012A5
JP2006514012A5 JP2004555329A JP2004555329A JP2006514012A5 JP 2006514012 A5 JP2006514012 A5 JP 2006514012A5 JP 2004555329 A JP2004555329 A JP 2004555329A JP 2004555329 A JP2004555329 A JP 2004555329A JP 2006514012 A5 JP2006514012 A5 JP 2006514012A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
compound according
acceptable salt
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004555329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514012A (ja
JP4542906B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/032747 external-priority patent/WO2004048382A1/en
Publication of JP2006514012A publication Critical patent/JP2006514012A/ja
Publication of JP2006514012A5 publication Critical patent/JP2006514012A5/ja
Application granted granted Critical
Publication of JP4542906B2 publication Critical patent/JP4542906B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004555329A 2002-11-22 2003-11-10 キノリニル−ピロロピラゾール類 Expired - Fee Related JP4542906B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42889302P 2002-11-22 2002-11-22
PCT/US2003/032747 WO2004048382A1 (en) 2002-11-22 2003-11-10 Quinolinyl-pyrrolopyrazoles

Publications (3)

Publication Number Publication Date
JP2006514012A JP2006514012A (ja) 2006-04-27
JP2006514012A5 true JP2006514012A5 (US20050137174A1-20050623-C00027.png) 2006-12-14
JP4542906B2 JP4542906B2 (ja) 2010-09-15

Family

ID=32393478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004555329A Expired - Fee Related JP4542906B2 (ja) 2002-11-22 2003-11-10 キノリニル−ピロロピラゾール類

Country Status (29)

Country Link
US (2) US7265225B2 (US20050137174A1-20050623-C00027.png)
EP (1) EP1565471B1 (US20050137174A1-20050623-C00027.png)
JP (1) JP4542906B2 (US20050137174A1-20050623-C00027.png)
KR (1) KR101057282B1 (US20050137174A1-20050623-C00027.png)
CN (1) CN100345852C (US20050137174A1-20050623-C00027.png)
AT (1) ATE341550T1 (US20050137174A1-20050623-C00027.png)
AU (1) AU2003291643B2 (US20050137174A1-20050623-C00027.png)
BR (1) BR0315337A (US20050137174A1-20050623-C00027.png)
CA (1) CA2501322C (US20050137174A1-20050623-C00027.png)
CO (1) CO5570677A2 (US20050137174A1-20050623-C00027.png)
CR (1) CR7830A (US20050137174A1-20050623-C00027.png)
CY (1) CY1106283T1 (US20050137174A1-20050623-C00027.png)
DE (1) DE60308893T2 (US20050137174A1-20050623-C00027.png)
DK (1) DK1565471T3 (US20050137174A1-20050623-C00027.png)
EA (1) EA008387B1 (US20050137174A1-20050623-C00027.png)
EC (1) ECSP055807A (US20050137174A1-20050623-C00027.png)
EG (1) EG25822A (US20050137174A1-20050623-C00027.png)
ES (1) ES2273046T3 (US20050137174A1-20050623-C00027.png)
HK (1) HK1081948A1 (US20050137174A1-20050623-C00027.png)
HR (1) HRP20050436B1 (US20050137174A1-20050623-C00027.png)
IL (1) IL168190A (US20050137174A1-20050623-C00027.png)
MX (1) MXPA05005432A (US20050137174A1-20050623-C00027.png)
NO (1) NO331403B1 (US20050137174A1-20050623-C00027.png)
NZ (1) NZ538942A (US20050137174A1-20050623-C00027.png)
PL (1) PL227840B1 (US20050137174A1-20050623-C00027.png)
PT (1) PT1565471E (US20050137174A1-20050623-C00027.png)
UA (1) UA80571C2 (US20050137174A1-20050623-C00027.png)
WO (1) WO2004048382A1 (US20050137174A1-20050623-C00027.png)
ZA (1) ZA200503121B (US20050137174A1-20050623-C00027.png)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003290734A1 (en) * 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
US7872020B2 (en) * 2005-07-22 2011-01-18 Eli Lilly And Company TGF-β inhibitors
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
EP2918288B1 (en) 2006-10-03 2017-08-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
KR20090066297A (ko) * 2006-10-16 2009-06-23 화이자 프로덕츠 인크. 치료용 피라졸릴 티에노피리딘
JP5806735B2 (ja) 2010-07-02 2015-11-10 ギリアード サイエンシーズ, インコーポレイテッド Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
AP2015008931A0 (en) 2011-04-21 2015-12-31 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
WO2013078286A1 (en) 2011-11-22 2013-05-30 Cornell University Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA032679B1 (ru) 2012-10-05 2019-07-31 Кадмон Корпорейшн, Ллк Человеческие анти-vegfr-2/kdr-антитела
ES2791627T3 (es) 2012-11-12 2020-11-05 Inst Catalana Recerca Estudis Avancats Métodos y kits para el pronóstico del cáncer colorrectal
JO3336B1 (ar) 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
JP6856648B2 (ja) 2015-12-15 2021-04-07 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cxcr4受容体アンタゴニスト
US10604528B2 (en) 2016-07-07 2020-03-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Galunisertib crystalline form, preparation method thereof and use thereof
US11111248B2 (en) 2017-03-17 2021-09-07 Hangzhou Solipharma Co., Ltd. Crystal form of 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4H-pyrrolo[1,2-B]pyrazole, preparation method therefor and pharmaceutical composition thereof
WO2018170724A1 (zh) 2017-03-21 2018-09-27 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
US20210309679A1 (en) 2018-07-23 2021-10-07 Guangzhou Othrotx Co., Ltd. Bisphosphonate drug conjugates
MX2021007738A (es) 2018-12-27 2021-08-05 Nexys Therapeutics Inc Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer.
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
CN113557236B (zh) * 2019-06-10 2022-05-10 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
JP2023514324A (ja) 2020-02-19 2023-04-05 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
ES2222919T3 (es) * 1999-08-27 2005-02-16 Abbott Laboratories Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2.
DE60221392T2 (de) * 2001-05-24 2008-04-17 Eli Lilly And Co., Indianapolis Neue pyrrolderivate als pharmazeutische mittel
JP2006522735A (ja) 2002-11-21 2006-10-05 イーライ リリー アンド カンパニー ミックス系統キナーゼモジュレータ

Similar Documents

Publication Publication Date Title
JP2006514012A5 (US20050137174A1-20050623-C00027.png)
JP2009502743A5 (US20050137174A1-20050623-C00027.png)
JP2005518413A5 (US20050137174A1-20050623-C00027.png)
JP2007522220A5 (US20050137174A1-20050623-C00027.png)
JP2009545527A5 (US20050137174A1-20050623-C00027.png)
JP2020097577A5 (US20050137174A1-20050623-C00027.png)
JP2005523922A5 (US20050137174A1-20050623-C00027.png)
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
JP2006526031A5 (US20050137174A1-20050623-C00027.png)
JP2016006096A5 (US20050137174A1-20050623-C00027.png)
JP2005508905A5 (US20050137174A1-20050623-C00027.png)
JP2010526814A5 (US20050137174A1-20050623-C00027.png)
JP2012532874A5 (US20050137174A1-20050623-C00027.png)
HRP20120803T1 (hr) Prolijekovi alkilatora fosforamidata
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
RS20080002A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP2008535902A5 (US20050137174A1-20050623-C00027.png)
JP2004534850A5 (US20050137174A1-20050623-C00027.png)
JP2009520695A5 (US20050137174A1-20050623-C00027.png)
JP2006509749A5 (US20050137174A1-20050623-C00027.png)
JP2013518107A5 (US20050137174A1-20050623-C00027.png)
JP2008511597A5 (US20050137174A1-20050623-C00027.png)
CY1110631T1 (el) Διαλυτοποιημενα δηλητηρια τοποϊσομερασης
CA2501322A1 (en) Quinolinyl-pyrrolopyrazoles
JP2019524883A5 (US20050137174A1-20050623-C00027.png)